Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient Jul 7, 2023 | Uncategorized
Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma Jul 7, 2023 | Uncategorized
Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study Oct 4, 2020 | Merkel Cell Carcinoma
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells Jul 7, 2020 | Head & Neck
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations May 20, 2020 | Non-Small Cell Lung Cancer, Triple Negative Breast Cancer